Accéder au contenu
Merck

Comprehensive and Reproducible Untargeted Lipidomic Workflow Using LC-QTOF Validated for Human Plasma Analysis.

Journal of proteome research (2018-09-27)
Anik Forest, Matthieu Ruiz, Bertrand Bouchard, Gabrielle Boucher, Olivier Gingras, Caroline Daneault, Isabelle Robillard Frayne, David Rhainds, Jean-Claude Tardif, John D Rioux, Christine Des Rosiers
RÉSUMÉ

The goal of this work was to develop a label-free, comprehensive, and reproducible high-resolution liquid chromatography-mass spectrometry (LC-MS)-based untargeted lipidomic workflow using a single instrument, which could be applied to biomarker discovery in both basic and clinical studies. For this, we have (i) optimized lipid extraction and elution to enhance coverage of polar and nonpolar lipids as well as resolution of their isomers, (ii) ensured MS signal reproducibility and linearity, and (iii) developed a bioinformatic pipeline to correct remaining biases. Workflow validation is reported for 48 replicates of a single human plasma sample: 1124 reproducible LC-MS signals were extracted (median signal intensity RSD = 10%), 50% of which are redundant due to adducts, dimers, in-source fragmentation, contaminations, or positive and negative ion duplicates. From the resulting 578 unique compounds, 428 lipids were identified by MS/MS, including acyl chain composition, of which 394 had RSD < 30% inside their linear intensity range, thereby enabling robust semiquantitation. MS signal intensity spanned 4 orders of magnitude, covering 16 lipid subclasses. Finally, the power of our workflow is illustrated by a proof-of-concept study in which 100 samples from healthy human subjects were analyzed and the data set was investigated using three different statistical testing strategies in order to compare their capacity in identifying the impact of sex and age on circulating lipids.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Avanti
18:1 (Δ9-Cis) PE (DOPE), Avanti Research - A Croda Brand
Avanti
14:0 PC (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine, powder
Avanti
18:1 (Δ9-Cis) PE (DOPE), Avanti Research - A Croda Brand
Avanti
16:0 Lyso PC, Avanti Research - A Croda Brand
Avanti
14:0 PC (DMPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine, chloroform
Avanti
19:0 PC, Avanti Research - A Croda Brand
Avanti
C17 Ceramide (d18:1/17:0), Avanti Research - A Croda Brand
Avanti
C16 Glucosyl(β) Ceramide (d18:1/16:0), Avanti Research - A Croda Brand
Avanti
17:0 PE, Avanti Research - A Croda Brand
Avanti
16:0 Lyso PC, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine, chloroform
Avanti
18:0 Lyso PE, 1-Stearoyl-2-Hydroxy-sn-Glycero-3-Phosphoethanolamine, powder
Avanti
22:1 (Cis) PC, 1,2-dierucoyl-sn-glycero-3-phosphocholine, powder
Avanti
18:1 DG, Avanti Research - A Croda Brand
Avanti
18:0-18:2 PS, 1-stearoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine (sodium salt), powder
Avanti
18:1 DG, 1-2-dioleoyl-sn-glycerol, chloroform
Avanti
19:0 PC, 1,2-dinonadecanoyl-sn-glycero-3-phosphocholine, chloroform
Avanti
15:0 PG, 1,2-dipentadecanoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt), powder
Avanti
12:0 PS, 1,2-dilauroyl-sn-glycero-3-phospho-L-serine (sodium salt), powder
Avanti
12:0 PG, Avanti Research - A Croda Brand
Avanti
22:1 (Cis) PC, 1,2-dierucoyl-sn-glycero-3-phosphocholine, chloroform
Avanti
18:0-18:2 PS, 1-stearoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine (sodium salt), chloroform